Probiotics for Non-Alcoholic Fatty Liver Disease: What the Research Actually Shows
A peer-reviewed look at the gut-liver axis, how gut dysbiosis drives fatty liver, and which probiotic strains have the strongest clinical evidence for NAFLD — organized by mechanism and what the trials actually support
Non-alcoholic fatty liver disease affects roughly one in four adults worldwide — making it the most prevalent chronic liver disease on the planet — and most people who have it don't know it. Unlike alcohol-related liver damage, NAFLD develops in people who drink little or no alcohol, driven instead by metabolic dysfunction, insulin resistance, poor diet, and an increasingly recognized culprit: a disrupted gut microbiome.
The liver and gut are not isolated organs. They are anatomically connected by the portal vein — which carries blood from the intestines directly to the liver before it circulates anywhere else in the body — and functionally intertwined through a constant exchange of metabolites, bile acids, immune signals, and microbial products. When the gut microbiome becomes imbalanced, the liver bears the consequences first: bacterial endotoxins, pro-inflammatory byproducts, and pathogen-associated molecular patterns arrive at the liver via the portal circulation, activating immune cells and triggering the inflammatory cascade that turns simple fat accumulation into active liver injury.
This article covers what the peer-reviewed literature says about probiotics for NAFLD — the mechanisms, the clinical trial data from over three dozen randomized controlled trials, and the specific strains with the strongest evidence, all of which are present in MicroBiome Restore. We discuss only strains in our formula, and we won't overstate what the evidence supports. For the broader gut dysbiosis context, our companion article on gut dysbiosis and probiotic restoration covers the full microbiome imbalance picture. For related metabolic conditions closely tied to NAFLD, see our articles on probiotics for type 2 diabetes and blood sugar and probiotics for high cholesterol.
For a broader look at how probiotics support liver health across all liver conditions — including cirrhosis and alcohol-associated liver disease — see our comprehensive guide to probiotics for liver health, which covers the gut-liver axis, cirrhosis-specific RCT data, and the full mechanistic picture beyond NAFLD.
Key Takeaways
- NAFLD affects an estimated 25% of the global adult population and is the leading cause of chronic liver disease worldwide — with no FDA-approved pharmacological treatment currently available for the disease itself.[1]
- Gut dysbiosis is a key driver of NAFLD progression. NAFLD patients consistently show depleted Bifidobacterium and Lactobacillus populations and elevated pathogenic Proteobacteria and Enterobacteriaceae — increasing intestinal permeability and delivering LPS-driven inflammatory signals to the liver via the portal vein.[2]
- The LPS-TLR4 signaling pathway is the central molecular mechanism linking gut dysbiosis to hepatic inflammation, de novo lipogenesis, insulin resistance, and fibrosis in NAFLD.[3]
- A 2024 network meta-analysis of 35 RCTs found Lactobacillus + Bifidobacterium + Streptococcus to be the most effective probiotic combination for NAFLD, producing the greatest reductions in AST (SMD: −1.95), ALT (SMD: −1.67), GGT (SMD: −2.17), TNF-α (SMD: −1.73), LDL, total cholesterol, and BMI compared to all other probiotic combinations tested.[4]
- A 41-RCT meta-analysis confirmed that probiotics, prebiotics, and synbiotics significantly improve sonographic liver steatosis, fibrosis markers, and blood levels of ALT, AST, and GGT in NAFLD patients — with synbiotics showing the most consistent effects across the broadest outcome range.[5]
- VSL#3 — a multi-strain formula including Bifidobacterium breve, B. longum, B. infantis, S. thermophilus, L. acidophilus, L. plantarum, L. casei, and L. bulgaricus (all in MicroBiome Restore) — reduced moderate-to-severe liver steatosis to 9% vs. 93% in placebo in a double-blind RCT in pediatric NAFLD.[6]
- Synbiotics consistently outperform probiotics alone in NAFLD trials, with a 2024 meta-analysis of 34 double-blind RCTs documenting significant reductions in ALT (SMD: −0.48), AST (SMD: −0.35), TNF-α (SMD: −0.86), and HOMA-IR (SMD: −0.28) with synbiotic supplementation.[7]
- Probiotic safety in NAFLD is well-established. No adverse effects have been reported across clinical trials using Lactobacillus, Bifidobacterium, Bacillus, Streptococcus, Pediococcus, Enterococcus, or Lactococcus — all of which are present in MicroBiome Restore.[8]
What Is NAFLD — and Why Is It So Common?
Non-alcoholic fatty liver disease is defined by the accumulation of excess fat — specifically triglycerides — in more than 5% of hepatocytes, in the absence of significant alcohol consumption or other identifiable liver disease causes. The term covers a spectrum of conditions ranging from simple, reversible steatosis at one end to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma at the other.
The NAFLD Progression Spectrum
- Simple steatosis — Fat accumulation in >5% of hepatocytes; reversible with lifestyle intervention at this stage
- NASH (Non-alcoholic steatohepatitis) — Fat + active hepatocyte injury and inflammation; often asymptomatic but progressive
- Fibrosis — Scar tissue replacing damaged liver cells; partially reversible in early stages
- Cirrhosis — Extensive scarring with significant impairment of liver function; largely irreversible
- Hepatocellular carcinoma (HCC) — Liver cancer arising from chronic injury in cirrhosis
NAFLD now affects an estimated 25% of the global adult population — approximately 2 billion people — making it the most prevalent chronic liver disease worldwide.[1] Its prevalence is rising in parallel with rates of obesity, type 2 diabetes, and metabolic syndrome, with which it shares substantial pathophysiology. Critically, there is currently no FDA-approved pharmacological treatment for NAFLD specifically. Lifestyle modification — diet, physical activity, and weight loss — remains the primary recommended intervention, which creates genuine clinical interest in evidence-based adjuncts like probiotic supplementation that can complement, but not substitute for, lifestyle change.
What makes NAFLD particularly challenging to recognize and manage is that most people with simple steatosis or even early NASH are entirely asymptomatic. Elevated liver enzymes on routine bloodwork are often the first objective indicator, and many people learn about their fatty liver only when undergoing ultrasound for an unrelated reason. This is why understanding the upstream contributors — including gut microbiome dysfunction — is increasingly valuable, both for prevention and for supporting the management of established disease.
To understand where NAFLD fits in the broader landscape of metabolic health, our articles on probiotics for type 2 diabetes and blood sugar and probiotics for belly fat cover the metabolic pathways that overlap significantly with NAFLD pathogenesis.
The Gut-Liver Axis: How Your Microbiome Drives Fatty Liver
The gut-liver axis describes the bidirectional communication network connecting the gastrointestinal tract and the liver, mediated primarily by the portal vein. Blood from the intestines drains into the portal circulation and travels directly to the liver, meaning the liver is exposed to virtually everything absorbed from — or passing through — the gut before it reaches systemic circulation. In a healthy state with an intact mucosal barrier, this means nutrient-rich blood and beneficial metabolites. In a dysbiotic state with a compromised barrier, it means a constant low-level exposure to endotoxins, inflammatory bacterial byproducts, and microbial components that activate hepatic immune cells and drive liver injury.[3]
The gut microbiome of NAFLD patients displays a remarkably consistent signature across multiple studies: depleted Bifidobacterium and Lactobacillus populations, and elevated pathogenic Proteobacteria and Enterobacteriaceae. This dysbiotic profile drives three interconnected mechanisms of hepatic injury:[2]
The LPS-TLR4 Pathway: From Leaky Gut to Liver Inflammation
Gram-negative bacteria — which dominate in dysbiotic NAFLD microbiomes — have lipopolysaccharide (LPS) as a structural component of their outer membrane. In a healthy gut, LPS stays within the intestinal lumen. When tight junction proteins (ZO-1, occludin, claudin) are disrupted — through dysbiosis, high-fat diet, or metabolic stress — LPS translocates across the gut epithelium into the portal circulation. Once in the liver, LPS binds toll-like receptor 4 (TLR4) on Kupffer cells, activating the MyD88/NF-κB signaling cascade and triggering production of TNF-α, IL-6, and IL-1β.[3] This inflammatory wave promotes hepatic de novo lipogenesis, hepatocyte injury, activation of hepatic stellate cells (driving fibrosis), and insulin resistance. Crucially, TLR4-knockout mice fed high-fat diets develop dramatically less liver injury and steatohepatitis than wild-type controls — demonstrating that LPS-TLR4 signaling is mechanistically required for NAFLD progression, not merely associated with it.[9]
Beyond endotoxemia, gut dysbiosis in NAFLD disrupts two additional critical metabolic systems. Beneficial bacteria — particularly Bifidobacterium and Lactobacillus species — produce short-chain fatty acids (SCFAs) including butyrate, propionate, and acetate through fermentation of dietary fiber. NAFLD patients consistently show reduced fecal SCFA concentrations, and butyrate deficiency is directly associated with increased gut permeability and reduced hepatic fatty acid oxidation.[10] The microbiome also plays a critical role in secondary bile acid metabolism: dysbiosis disrupts bile acid conversion, altering the bile acid pool in ways that impair farnesoid X receptor (FXR) signaling in the liver — a receptor that normally helps regulate lipid metabolism, glucose homeostasis, and hepatic inflammation.
There is also a well-established connection between small intestinal bacterial overgrowth (SIBO) and NAFLD. NAFLD patients have significantly higher rates of SIBO than healthy controls, and SIBO elevates TNF-α and aminotransferase levels through the same endotoxemia pathway — creating a feedback loop that accelerates liver damage.
For a detailed look at the specific microbial deficits most characteristic of liver disease, our guides on Bifidobacterium deficiency and Lactobacillus deficiency signs and strains cover the clinical picture in depth.
How Probiotics Protect Against NAFLD: The Mechanisms
The liver-protective mechanisms of probiotics in NAFLD are well-characterized at the molecular level. Multiple pathways operate simultaneously — which is the mechanistic explanation for why multi-strain formulas consistently outperform single-strain products in NAFLD clinical trials.
🔒 Tight Junction Reinforcement
Lactobacillus and Bifidobacterium species upregulate tight junction proteins (ZO-1, occludin, claudin-1) in intestinal epithelial cells — physically sealing the paracellular spaces that allow LPS to pass into the portal circulation when disrupted.[11]
🔥 LPS and TLR4 Downregulation
By displacing Gram-negative pathogenic bacteria, probiotics reduce the source production of LPS — lowering the total endotoxin load reaching the liver and directly reducing TLR4 activation, NF-κB signaling, and pro-inflammatory cytokine output.[9]
⚡ Short-Chain Fatty Acid Production
Probiotic bacteria — especially when supported by prebiotic substrates — produce butyrate, propionate, and acetate. Butyrate fuels colonocytes (reducing gut permeability), activates PPAR-α (promoting hepatic fat oxidation), and suppresses SREBP-1c-driven de novo lipogenesis.[10]
🧪 Hepatic Lipid Metabolism Modulation
L. plantarum activates the AMPK pathway, phosphorylates ACC, and halts SREBP-1/FAS signaling — directly inhibiting hepatic fat synthesis at the molecular level. Bifidobacterium species independently suppress SREBP-1c transcription, reducing triglyceride and cholesterol accumulation in hepatocytes.[11]
🛡️ Bile Acid Regulation
Lactobacillus and Bifidobacterium express bile salt hydrolases (BSH) that deconjugate primary bile acids to secondary forms — restoring FXR signaling and normalizing the regulatory feedback loop governing hepatic lipid and glucose metabolism.[10]
💊 Antioxidant Activation
Certain strains — notably L. plantarum — significantly elevate hepatic superoxide dismutase (SOD) and glutathione (GSH) levels, reducing the oxidative stress that drives hepatocyte ballooning, NASH, and the transition from simple steatosis to inflammatory injury.[11]
These mechanisms also explain why synbiotics — probiotics combined with prebiotic substrates — consistently show stronger NAFLD outcomes than probiotics taken alone. Prebiotics provide the substrate that enables durable colonization and therapeutically meaningful SCFA production. MicroBiome Restore's prebiotic matrix — including Jerusalem artichoke inulin, acacia fiber, maitake mushroom beta-glucan, fig fruit, bladderwrack, Norwegian kelp, and oarweed — functions as exactly this ecosystem support, making it inherently synbiotic in its mechanism of action. For more on the butyrate side of the equation, our article on how to increase butyrate and SCFAs covers the evidence in depth.
Best Probiotic Strains for Fatty Liver
The following strains represent the species with the strongest peer-reviewed evidence for NAFLD-relevant outcomes.
Lactobacillus rhamnosus — Barrier Integrity and Endotoxemia Reduction
Lactobacillus rhamnosus GG is among the most studied probiotic strains in metabolic liver disease. In pediatric NAFLD, oral supplementation with L. rhamnosus GG significantly reduced ALT — a direct marker of hepatocellular injury — while stabilizing liver ultrasound scores and reducing TNF-α levels.[12] Mechanistically, LGG potentiates intestinal hypoxia-inducible factor (HIF) — a transcription factor that upregulates tight junction proteins under metabolic stress conditions — reinforcing the gut barrier against endotoxin translocation. More recently, L. rhamnosus GG has been shown to directly compete with intestinal fatty acid absorption in the gut, sharing dietary lipids with the host bacteria and reducing the fatty acids available for hepatic accumulation — a novel mechanism for preventing hepatic steatosis.[13] Our guide to Lactobacillus rhamnosus benefits covers the full evidence base for this strain.
Lactobacillus plantarum — Lipid Metabolism and Antioxidant Activation
Lactobacillus plantarum is the most extensively studied Lactobacillus species specifically in the context of NAFLD, addressing it through the AMPK/SREBP-1c pathway — directly inhibiting hepatic de novo lipogenesis — while simultaneously elevating antioxidant enzymes SOD and GSH that protect against oxidative hepatocyte damage.[11] L. plantarum combined with B. longum has been shown to reduce blood ALT, AST, γGTP, TNF-α, triglycerides, total cholesterol, total bile acids, and LPS levels simultaneously in liver injury models, acting through NF-κB and AMPK signaling suppression.[14] It appears consistently across multi-strain NAFLD trials as one of the core contributors to hepatic benefit. See our dedicated article on Lactobacillus plantarum health benefits for the broader clinical picture.
Bifidobacterium longum — NASH, Endotoxemia Reduction, and SCFA Production
The landmark clinical evidence for B. longum in NAFLD/NASH comes from a 24-week RCT by Malaguarnera et al., in which B. longum supplemented with fructooligosaccharides significantly reduced serum ALT, AST, total cholesterol, HOMA-IR, pro-inflammatory cytokines, hepatic steatosis grade, and the NASH activity index compared to lifestyle modification alone — a comprehensive outcome profile rarely achieved in a single NAFLD trial.[15] B. longum and B. breve together have also been shown to significantly improve NAFLD activity scores in Western diet models through SCFA production, bile acid deconjugation, and SREBP-1c suppression.[10] Our article on Bifidobacterium longum food sources and supplementation provides additional clinical context.
Bifidobacterium breve — NAFLD Activity Score and Steatosis Improvement
A 2024 meta-analysis of 13 RCTs examining Bifidobacterium-containing probiotics in NAFLD found significant reductions in liver fat severity and BMI among Bifidobacterium-treated patients.[16] B. breve was included in the landmark VSL#3 pediatric NAFLD trial, where the multi-strain formula (which includes both B. breve and several other strains present in MicroBiome Restore) reduced moderate-to-severe liver steatosis on histology to just 9% in the treatment group versus 93% in placebo — one of the most striking single-trial results in the NAFLD probiotic literature.[6]
Bifidobacterium infantis — VSL#3 Component for Pediatric Steatosis
Bifidobacterium infantis is one of the eight strains in VSL#3, the most studied multi-strain probiotic formula in NAFLD with multiple positive RCTs in both pediatric and adult populations. In the pediatric RCT by Alisi et al., the VSL#3 formula containing B. infantis (alongside B. breve, B. longum, S. thermophilus, L. acidophilus, L. plantarum, L. casei, and L. bulgaricus — all of which are present in MicroBiome Restore) produced the dramatic steatosis reduction described above while also significantly reducing BMI compared to placebo.[6] Our article on Bifidobacterium deficiency and gut health provides broader context on why these species matter.
Lactobacillus acidophilus — Antioxidant Defense and Insulin Sensitization
L. acidophilus appears in multiple positive NAFLD clinical trials as a core component of multi-strain formulas showing improvements in ALT, AST, steatosis, and insulin resistance. A meta-analysis of pediatric NAFLD studies specifically identified L. acidophilus in combination with other Bifidobacterium or Lactobacillus strains as producing statistically significant reductions in ALT (WMD = −7.51 IU/L), AST (WMD = −6.46 IU/L), triglycerides, and BMI, with zero heterogeneity across included trials.[17] It is also a key component of the Lactocare multi-strain formula (L. casei, L. acidophilus, L. rhamnosus, L. bulgaricus, B. breve, B. longum, S. thermophilus) that significantly reduced fasting blood sugar, insulin, HOMA-IR, TNF-α, and IL-6 in a double-blind NAFLD RCT compared to placebo.[8] Our article on Lactobacillus acidophilus dosage and clinical guidelines covers the evidence in full.
Lactobacillus casei — Lipid Profile and Synbiotic Partner
L. casei is a consistent component of the best-performing multi-strain formulas in NAFLD trials, including both VSL#3 and the Lactocare and Shavakhi synbiotic combinations. In a 6-month RCT by Shavakhi et al. in NAFLD patients, a synbiotic containing L. acidophilus, L. casei, L. rhamnosus, L. bulgaricus, B. breve, B. longum, S. thermophilus, and FOS produced significantly greater reductions in ALT, AST, blood triglycerides, cholesterol, and BMI compared to metformin alone — with grade 2–3 hepatic steatosis falling to 0% in the synbiotic arm versus 46.9% in the metformin-only arm at 6 months.[8]
Lactobacillus delbrueckii subsp. bulgaricus + Streptococcus thermophilus — Liver Enzyme Reduction in Adults
The Aller et al. RCT evaluated L. bulgaricus and S. thermophilus supplementation in adult NAFLD patients over 3 months. The probiotic group showed significant improvements in liver enzyme levels and cholesterol compared to placebo.[18] These two strains appear together consistently in yogurt-based delivery systems studied in NAFLD, and their combination contributes to the composite efficacy of multi-strain formulas. Our article on Streptococcus thermophilus benefits covers this strain's broader clinical evidence in gut health and beyond.
Pediococcus acidilactici and Pediococcus pentosaceus — Endotoxin Reduction and Gut-Liver Barrier Support
Pediococcus pentosaceus was included in the Jun et al. double-blind, placebo-controlled RCT of a 6-strain probiotic mixture (also including L. acidophilus, L. rhamnosus, L. paracasei, B. lactis, and B. breve) in 68 obese NAFLD patients, which measured intrahepatic fat fraction by MRI-PDFF — a more precise endpoint than ultrasound or enzymes alone. The probiotic group showed a significant reduction in intrahepatic fat fraction compared to placebo (p = 0.012), along with reductions in body weight and total body fat, while the placebo group showed no change.[19] This is one of the few NAFLD trials to use MRI-based fat quantification as a primary endpoint, making its findings particularly compelling. Our article on Pediococcus acidilactici probiotic benefits covers this genus in depth.
Lactobacillus paracasei — Multi-Strain Partner for Intrahepatic Fat Reduction
L. paracasei appeared alongside Pediococcus pentosaceus in the Jun et al. MRI-based NAFLD RCT described above, contributing to the significant intrahepatic fat reduction observed in the 12-week trial.[19] It also appears in the Lactocare multi-strain combination and multiple other positive NAFLD trials, making it a reliable multi-strain synergist rather than a standalone intervention.
Bifidobacterium lactis — Visceral Fat and Intrahepatic Fat Reduction
B. lactis was included in the Jun et al. MRI-based RCT and has also been studied in combination with other probiotic strains (L. acidophilus, L. rhamnosus DSMZ 21690, and B. bifidum) showing reductions in intrahepatic fat content and sonographic liver lipid profiles in NAFLD patients.[20] Our article on Bifidobacterium lactis benefits for gut health provides the broader clinical evidence for this species.
Every Strain Listed Here. One Filler-Free Formula.
MicroBiome Restore contains all of the Lactobacillus, Bifidobacterium, Streptococcus, and Pediococcus strains discussed in this article — plus additional evidence-backed species — delivering 15 billion CFU per serving with 7 certified organic prebiotic sources and zero manufacturing fillers.
| Strain (in MicroBiome Restore) | Primary NAFLD Mechanism | Key Evidence |
|---|---|---|
| L. rhamnosus | Tight junction reinforcement, HIF activation, intestinal fatty acid competition | Significant ALT reduction in pediatric NAFLD RCT; reduces LPS translocation[12][13] |
| L. plantarum | AMPK/SREBP-1c pathway, de novo lipogenesis inhibition, SOD/GSH elevation | Reduces ALT, AST, γGTP, TNF-α, LPS, TLR4 gene expression via NF-κB/AMPK[11][14] |
| B. longum | LPS/endotoxemia reduction, NASH activity index improvement, SCFA production | 24-week NASH RCT: reduced ALT, AST, TC, HOMA-IR, cytokines, steatosis grade[15] |
| B. breve | NAFLD activity score reduction, SCFA production, bile acid deconjugation | VSL#3 RCT: 9% moderate-severe steatosis vs. 93% placebo in pediatric NAFLD[6] |
| B. infantis | VSL#3 component; intestinal barrier support, steatosis reduction | Pediatric NAFLD RCT: significant steatosis and BMI reduction[6] |
| L. acidophilus | Insulin sensitization, antioxidant defense, TLR4 suppression | Pediatric meta-analysis: ALT WMD −7.51 IU/L, AST WMD −6.46 IU/L (I²=0%)[17] |
| L. casei | Multi-strain synergy for lipid reduction and steatosis reversal | Synbiotic RCT: 0% grade 2–3 steatosis at 6 months vs. 46.9% metformin-only[8] |
| S. thermophilus + L. bulgaricus | Liver enzyme reduction | 3-month adult NAFLD RCT: significant liver enzyme and cholesterol improvement[18] |
| P. pentosaceus | Intrahepatic fat reduction (MRI-confirmed), gut-liver barrier support | Double-blind NAFLD RCT: significant intrahepatic fat fraction reduction vs. placebo (MRI-PDFF)[19] |
| B. lactis | Intrahepatic fat content, sonographic lipid profile improvement | Multi-strain NAFLD studies: reduced intrahepatic fat, ALT, sonographic steatosis[20] |
Clinical Evidence: What the RCTs and Meta-Analyses Show
The clinical evidence base for probiotics in NAFLD is now substantial — arguably among the strongest for any adjunctive intervention in this disease. Several meta-analyses synthesizing data from dozens of randomized controlled trials have reached consistent conclusions, and the 2024 network meta-analysis comparing different probiotic combinations head-to-head is particularly important for guiding formulation decisions.
The 2024 Network Meta-Analysis: Identifying the Best Combination
A 2024 systematic review and network meta-analysis by Yang et al. included 35 RCTs involving 2,212 NAFLD patients and directly compared the efficacy of different probiotic combinations against each other — not just against placebo.[4] The findings were clear: the combination of Lactobacillus + Bifidobacterium + Streptococcus demonstrated the highest probability of being the most effective combination across every primary outcome measured, producing the greatest reductions in:
This combination — Lactobacillus genera, Bifidobacterium genera, and Streptococcus thermophilus — maps precisely onto the core genera in MicroBiome Restore. The network meta-analysis methodology allows comparison between different treatments even when they haven't been tested head-to-head in direct trials, making it the highest-quality evidence available for comparative probiotic selection in NAFLD.
The 41-RCT Meta-Analysis: Steatosis, Fibrosis, and Enzymes
A 2023 systematic review and meta-analysis by Rong et al. in the Journal of Gastroenterology and Hepatology included 41 RCTs (18 probiotic, 17 synbiotic, 6 prebiotic) and found that microbiome-targeted therapies were associated with significant improvements in liver-related outcomes across all three modalities.[5] Synbiotics showed the most consistent improvements in liver enzymes (ALT, AST, GGT), with probiotics showing strong effects on steatosis by ultrasound and fibrosis scores, and prebiotics primarily improving metabolic markers. The analysis found that improvements in liver steatosis on imaging — a clinically meaningful hard endpoint — were achievable with probiotic supplementation, though effects on fibrosis were less consistent and more dependent on treatment duration.
The 34-RCT Meta-Analysis: Synbiotics for ALT, AST, and Inflammation
The 2024 meta-analysis by Pan et al. in BMC Gastroenterology focused specifically on probiotics, prebiotics, and synbiotics analyzed separately, using 34 double-blind RCTs.[7] Synbiotic supplementation produced statistically significant reductions in ALT (SMD: −0.48), AST (SMD: −0.35), TNF-α (SMD: −0.86), and HOMA-IR (SMD: −0.28) — all key NAFLD outcome markers — compared to placebo. The consistent advantage of synbiotics over probiotic-only interventions in this and other meta-analyses is mechanistically explained: prebiotic substrates support durable probiotic colonization and enable higher SCFA production, both of which amplify the liver-protective effects.
Pediatric NAFLD: VSL#3 and the 9% vs. 93% Steatosis Finding
One of the most striking single-trial results in the NAFLD literature involves VSL#3 in obese children with biopsy-proven NAFLD. In this double-blind 4-month RCT by Alisi et al., children receiving the 8-strain probiotic mixture (containing B. breve, B. longum, B. infantis, S. thermophilus, L. acidophilus, L. plantarum, L. casei, and L. bulgaricus — all present in MicroBiome Restore) had only 9% moderate-to-severe liver steatosis at end of treatment, compared to 93% in the placebo group.[6] BMI decrease was also significantly greater in the VSL#3 group. This is a pre-post comparison within a placebo-controlled design, and it represents one of the strongest histological outcomes documented for any probiotic intervention in pediatric NAFLD.
The MRI-Based Trial: Intrahepatic Fat Reduction Confirmed by Imaging
Jun et al. conducted a double-blind, placebo-controlled 12-week RCT in 68 obese NAFLD adults using MRI proton density fat fraction (MRI-PDFF) — a precise, quantitative imaging method — as the primary endpoint.[19] The 6-strain probiotic mixture (L. acidophilus, L. rhamnosus, L. paracasei, Pediococcus pentosaceus, B. lactis, and B. breve) significantly reduced intrahepatic fat fraction compared to baseline (p = 0.032) and compared to placebo (mean difference: −2.61%, p = 0.012). Body weight and total body fat also decreased significantly in the probiotic group. This trial is notable because it uses objective imaging confirmation — not just liver enzyme proxy markers — to document fat reduction in the liver.
Important Context on the Evidence
While the clinical evidence for probiotics in NAFLD is encouraging and now substantial, several limitations apply across the literature: heterogeneity in probiotic strains, dosages, formulations, and intervention durations makes direct comparisons difficult; most trials are 8–24 weeks, so long-term effects are less well established; and effects on liver histology (requiring biopsy) are less consistently studied than enzyme or ultrasound outcomes. Probiotics are best understood as a supportive adjunct to lifestyle modification — not a standalone treatment — and anyone with established NAFLD or NASH should be managed in partnership with a physician or hepatologist.
The Synbiotic Advantage for NAFLD
One of the most consistent findings across NAFLD clinical research is that synbiotics — formulas combining probiotic bacteria with prebiotic substrates — produce more reliable and broader improvements than probiotics or prebiotics used in isolation. This isn't a subtle trend; it shows up repeatedly across independent meta-analyses and is mechanistically well-explained.
The 2023 meta-analysis on synbiotics in NAFLD by Cheng et al., which included trials published through 2022, found that synbiotic supplementation significantly reduced total cholesterol (MD = −11.93), LDL (MD = −16.20), and increased HDL (MD = 1.56) — alongside improvements in liver enzymes — effects that were less consistently seen with probiotics alone.[21] The lipid profile improvements are particularly relevant because dyslipidemia is both a driver of NAFLD progression and a consequence of hepatic fat accumulation and insulin resistance.
Why do synbiotics outperform? Prebiotic substrates that selectively feed Bifidobacterium and Lactobacillus — like the inulin-type fructooligosaccharides (ITFs) found in Jerusalem artichoke, which is in MicroBiome Restore — serve multiple functions simultaneously: they feed the probiotic bacteria you're supplementing, enabling better colonization and higher SCFA output; they independently increase Bifidobacterium populations already resident in the gut; they reduce serum LPS (studies have documented normalized plasma endotoxin levels with ITF prebiotic therapy in NAFLD patients); and they improve glucose tolerance and reduce gut permeability through their own fermentation-derived effects.[2]
Inulin and other fructooligosaccharides have also been shown to activate PPARα gene transcription in the liver — directly inhibiting the SREBP-1c pathway that drives hepatic fat synthesis — through a mechanism that operates in parallel with the AMPK pathway activated by L. plantarum. This convergence of prebiotic and probiotic mechanisms on the same hepatic lipid targets likely explains why synbiotic combinations produce more robust and consistent steatosis reduction than either component alone.
Why MicroBiome Restore Is an Inherently Synbiotic Product
MicroBiome Restore doesn't just include probiotic strains alongside token prebiotic amounts. Its prebiotic matrix — Jerusalem artichoke (inulin), acacia fiber, maitake mushroom beta-glucan, fig fruit, bladderwrack, Norwegian kelp, oarweed, and pullulan capsules — is designed specifically to selectively feed and sustain the 26 strains in the formula. Every prebiotic ingredient listed is certified organic and has a functional reason for being there. Maltodextrin is used as a cryoprotectant to maintain strain viability during storage — a standard, well-validated stabilization approach — not as a filler. Nothing in the formula is there for manufacturing convenience. You can read more about our ingredient philosophy in our article on flow agents, fillers, and probiotics: the truth.
How to Choose a Probiotic for NAFLD Support
The supplement market for probiotics is poorly standardized, and the gap between label claims and evidence-supported products is substantial. Here is what actually matters when selecting a probiotic for liver health support.
Multi-Strain Is Not Optional for NAFLD
The liver-protective mechanisms of probiotics — barrier reinforcement, LPS reduction, SCFA production, bile acid modulation, antioxidant activation, lipid metabolism regulation — operate through multiple independent pathways. No single strain addresses all of them. Every positive NAFLD trial with histological outcomes (including the VSL#3 pediatric study and the Malaguarnera NASH trial) used multi-strain formulas. The 2024 network meta-analysis was explicitly designed to identify the best combination, not the best single strain, because single-strain approaches have lower and more variable efficacy.[4] A product claiming NAFLD liver benefits based on a single strain should be viewed with significant skepticism.
Prebiotic Support Is Equally Important
As detailed in the synbiotics section, the consistently superior outcomes of synbiotics over probiotics alone in NAFLD meta-analyses are mechanistically explained — and the gap is not marginal. If you're selecting a probiotic specifically to support liver health through the gut-liver axis, choosing a formula that includes evidence-based prebiotic substrates isn't optional; it's the difference between a product that approximates the clinical evidence and one that doesn't.
Avoid Products With Fillers That Undermine the Purpose
If you're supporting the gut microbiome to improve liver health, adding compounds with documented effects on gut microbial communities or intestinal permeability in the inactive ingredients doesn't make sense. Microcrystalline cellulose (MCC), magnesium stearate, and silicon dioxide are standard manufacturing additives with no biological benefit. MicroBiome Restore uses none of these. For guidance on reading probiotic labels accurately, our article on how to read probiotic supplement labels and spot hidden fillers provides a practical framework.
Capsule Quality and Strain Stability
Most probiotics use hypromellose (HPMC) capsules — a synthetic cellulose-based polymer. MicroBiome Restore uses pullulan capsules — fermented from tapioca, with documented prebiotic properties — which means the capsule itself contributes to feeding beneficial bacteria in the gut rather than simply carrying them. Our strains are lyophilized with maltodextrin as a cryoprotectant for viability during storage — a standard, well-validated method that maintains CFU counts, not a filler.
What to Look For vs. What to Avoid
Look for: Multi-strain formula with named Lactobacillus and Bifidobacterium species studied in NAFLD (L. rhamnosus, L. plantarum, L. acidophilus, L. casei, B. longum, B. breve, B. infantis); Streptococcus thermophilus; accompanying prebiotic substrates that feed beneficial bacteria (synbiotic formulation); clearly disclosed CFU count per serving; filler-free formulation; quality capsule material.
Avoid: Single-strain products claiming liver benefits; formulas with microcrystalline cellulose, magnesium stearate, silicon dioxide, or titanium dioxide in inactive ingredients; proprietary blends that obscure individual strain doses; brands making explicit claims about "treating" or "curing" NAFLD (regulatory red flag); products without disclosed CFU counts; formulas with no prebiotic component if liver support is the goal.
26 Strains. 7 Certified Organic Prebiotics. Zero Fillers.
MicroBiome Restore delivers every probiotic genus and species from the best-performing NAFLD combinations — Lactobacillus, Bifidobacterium, Streptococcus, Pediococcus — alongside 7 certified organic prebiotic substrates, 15 billion CFU per serving, and no manufacturing aids that don't belong in a formula built for microbiome health.
Frequently Asked Questions
Can probiotics reverse fatty liver disease?
The evidence doesn't support a claim that probiotics reverse established structural liver damage. What the clinical evidence does support is that probiotics — particularly multi-strain formulas taken as synbiotics — can reduce the key drivers of NAFLD progression: endotoxemia, hepatic inflammation, oxidative stress, insulin resistance, and de novo lipogenesis. Several trials have documented measurable reductions in liver steatosis on ultrasound and MRI imaging, and improvements in fibrosis scores have been observed in trials using synbiotics over 24 weeks. For early-stage NAFLD in the context of lifestyle intervention, synbiotic supplementation represents a genuinely promising adjunct. For established NASH or fibrosis, it should be part of a medically supervised management plan.
What is the best probiotic combination for fatty liver?
Based on the 2024 network meta-analysis of 35 RCTs, the best-evidenced combination is one containing all three genera: Lactobacillus + Bifidobacterium + Streptococcus.[4] Within those genera, the species with the strongest individual evidence for NAFLD include L. rhamnosus, L. plantarum, L. acidophilus, L. casei, B. longum, B. breve, B. infantis, and S. thermophilus. These are all present in MicroBiome Restore alongside additional evidence-supported strains.
How long does it take for probiotics to improve fatty liver markers?
Most positive NAFLD RCTs used intervention periods of 8 to 24 weeks before statistically significant enzyme improvements were documented. The shortest intervention periods (8–12 weeks) typically showed improvements in liver enzymes (ALT, AST) and metabolic markers; improvements in liver steatosis on imaging tended to require 12–24 weeks; and changes in fibrosis scores were most consistently documented at 24 weeks. Consistent daily supplementation over this period is necessary, as the microbiome-normalizing effects take time to establish and are not sustained without ongoing support.
Is fatty liver connected to gut health more broadly?
Very much so. The gut-liver axis means that virtually anything affecting the gut microbiome — diet, antibiotics, stress, SIBO, dysbiosis — has downstream consequences for the liver. Our articles on probiotics for leaky gut, probiotics for SIBO, and gut dysbiosis and probiotic restoration cover these adjacent conditions in clinical depth.
Can someone with NAFLD and type 2 diabetes benefit from probiotics?
Yes — and the synergies are well-documented. NAFLD and type 2 diabetes share insulin resistance as a core driver, and the same probiotic mechanisms that reduce hepatic fat accumulation (SCFA production, AMPK activation, HOMA-IR reduction) also improve glycemic control. Multiple NAFLD trials specifically measured and documented improvements in fasting blood sugar, insulin levels, and HOMA-IR in the probiotic groups. The Shavakhi synbiotic trial, for example, combined metformin with a Lactobacillus + Bifidobacterium synbiotic and showed significantly greater metabolic improvements than metformin alone. Our article on probiotics for type 2 diabetes and blood sugar covers the evidence in full.
Are probiotics safe for people with fatty liver disease?
Yes — the clinical evidence is consistent on this point. No adverse effects have been reported across dozens of NAFLD RCTs using Lactobacillus, Bifidobacterium, Streptococcus, Pediococcus, Enterococcus, or Bacillus species.[8] These genera fall within the GRAS (Generally Recognized as Safe) category and have well-established safety profiles in metabolic disease populations. As with any supplement, people with advanced cirrhosis, compromised immune function, or other complex liver conditions should consult their physician before starting probiotic supplementation.
References
- Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. https://pubmed.ncbi.nlm.nih.gov/26707365/
- Cao C, Shi M, Wang X, Yao Y, Zeng R. Effects of probiotics on non-alcoholic fatty liver disease: A review of human clinical trials. Frontiers in Nutrition. 2023;10:1155306. https://doi.org/10.3389/fnut.2023.1155306
- Hartmann P, Seyfrid N, Kaufmann B. The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. PMC. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC8926958/
- Yang Y, Yang L, Wu J, et al. Optimal probiotic combinations for treating nonalcoholic fatty liver disease: A systematic review and network meta-analysis. Clinical Nutrition. 2024;43(6):1355–1364. https://pubmed.ncbi.nlm.nih.gov/38643738/
- Rong L, Ch'ng D, Jia P, et al. Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology. 2023;38(10):1682–1694. https://pubmed.ncbi.nlm.nih.gov/37409560/
- Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 2014;39(11):1276–1285. As cited in: Frontiers in Microbiology Gut Microbiota Therapy for NAFLD Review (2022). https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.1004911/full
- Pan Y, Yang Y, Wu J, Zhou H, Yang C. Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterology. 2024;24(1):283. https://pmc.ncbi.nlm.nih.gov/articles/PMC11342484/
- Shavakhi A, Minakari M, Firouzian H, et al. Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: a double blind randomized clinical trial. International Journal of Preventive Medicine. 2013;4(5):531–537; and Sepideh A, et al. (Lactocare trial). As cited in: Frontiers in Microbiology Gut Microbiota Therapy for NAFLD Review (2022). https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.1004911/full
- Rivera CA, Adegboyega P, van Rooijen N, et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. Journal of Hepatology. 2007;47(4):571–579. As cited in: PMC Role of Gut Dysbiosis in Liver Diseases (2020). https://pmc.ncbi.nlm.nih.gov/articles/PMC6956030/
- Bifidobacterium-derived short-chain fatty acids and indole compounds attenuate NAFLD by modulating gut-liver axis. PMC. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10014915/
- Lu J, Shataer D, Yan H, et al. Probiotics and Non-Alcoholic Fatty Liver Disease: Unveiling the Mechanisms of Lactobacillus plantarum and Bifidobacterium bifidum in Modulating Lipid Metabolism, Inflammation, and Intestinal Barrier Integrity. Foods. 2024;13(18):2992. https://www.mdpi.com/2304-8158/13/18/2992
- Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. Journal of Pediatric Gastroenterology and Nutrition. 2011;52(6):740–743. https://pubmed.ncbi.nlm.nih.gov/21464757/
- Kim D, Yoo J, Kim W, et al. A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption. Experimental & Molecular Medicine. 2019;51(8):1–14. https://www.nature.com/articles/s12276-019-0293-4
- Kim WG, et al. Lactobacillus plantarum LC27 and Bifidobacterium longum LC67 alleviate liver injury and fibrosis by regulating NF-κB and AMPK signaling. Journal of Microbiology and Biotechnology. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10840473/
- Malaguarnera M, Vacante M, Antic T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Digestive Diseases and Sciences. 2012;57(2):545–553. https://doi.org/10.1007/s10620-011-1887-4
- Hwang SY, et al. Meta-analysis reveals Bifidobacterium as a promising probiotic in NAFLD management. Tungs' Medical Journal. 2024. https://journals.lww.com/tmj/
- Famouri F, Shariat Z, Hashemipour M, et al. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. Journal of Pediatric Gastroenterology and Nutrition. 2017;64(3):413–417; and Elnagdy M, et al. The benefit of probiotics in pediatric nonalcoholic fatty liver disease: A meta-analysis of randomized control trials. PubMed. 2022. https://pubmed.ncbi.nlm.nih.gov/35758473/
- Aller R, De Luis DA, Izaola O, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. European Review for Medical and Pharmacological Sciences. 2011;15(9):1090–1095. As cited in: Frontiers in Gastroenterology NAFLD Review (2024). https://www.frontiersin.org/journals/gastroenterology/articles/10.3389/fgstr.2024.1534431/full
- Jun DW, Cho YK, Jun JH, et al. Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. Scientific Reports. 2019;9:5049. https://www.nature.com/articles/s41598-019-42059-3
- Kim TH, et al. Multi-strain probiotic including Bifidobacterium lactis reduces intrahepatic fat content and ALT in NAFLD patients. As cited in: The Anti-Inflammatory and Curative Exponent of Probiotics (PMC 2024). https://pmc.ncbi.nlm.nih.gov/articles/PMC10893534/
- Cheng J, Du J. Synbiotics in patients with NAFLD: A systematic review and meta-analysis. Therapeutic Advances in Gastroenterology. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10302525/
Support Your Liver from the Inside Out
MicroBiome Restore delivers 26 probiotic strains — including every genus and species from the best-performing NAFLD combinations in the clinical literature — alongside 7 certified organic prebiotic substrates. Filler-free. 15 billion CFU. Formulated without microcrystalline cellulose, magnesium stearate, or any manufacturing aids that don't serve your microbiome.
'%3e%3cg%20id='Final-Copy-2_2_'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st0'%20d='M7.4,12.8h6.8l3.1-11.6H7.4C4.2,1.2,1.6,3.8,1.6,7S4.2,12.8,7.4,12.8z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3cg%20id='final---dec.11-2020'%3e%3cg%20id='_x30_208-our-toggle'%20transform='translate(-1275.000000,%20-200.000000)'%3e%3cg%20id='Final-Copy-2'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st1'%20d='M22.6,0H7.4c-3.9,0-7,3.1-7,7s3.1,7,7,7h15.2c3.9,0,7-3.1,7-7S26.4,0,22.6,0z%20M1.6,7c0-3.2,2.6-5.8,5.8-5.8%20h9.9l-3.1,11.6H7.4C4.2,12.8,1.6,10.2,1.6,7z'/%3e%3cpath%20id='x'%20class='st2'%20d='M24.6,4c0.2,0.2,0.2,0.6,0,0.8l0,0L22.5,7l2.2,2.2c0.2,0.2,0.2,0.6,0,0.8c-0.2,0.2-0.6,0.2-0.8,0%20l0,0l-2.2-2.2L19.5,10c-0.2,0.2-0.6,0.2-0.8,0c-0.2-0.2-0.2-0.6,0-0.8l0,0L20.8,7l-2.2-2.2c-0.2-0.2-0.2-0.6,0-0.8%20c0.2-0.2,0.6-0.2,0.8,0l0,0l2.2,2.2L23.8,4C24,3.8,24.4,3.8,24.6,4z'/%3e%3cpath%20id='y'%20class='st3'%20d='M12.7,4.1c0.2,0.2,0.3,0.6,0.1,0.8l0,0L8.6,9.8C8.5,9.9,8.4,10,8.3,10c-0.2,0.1-0.5,0.1-0.7-0.1l0,0%20L5.4,7.7c-0.2-0.2-0.2-0.6,0-0.8c0.2-0.2,0.6-0.2,0.8,0l0,0L8,8.6l3.8-4.5C12,3.9,12.4,3.9,12.7,4.1z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Your Privacy Choices
Share and get 15% off!
Simply share this product on one of the following social networks and you will unlock 15% off!